CIS Insulin Market by Products (Intermediate Insulin, Rapid Acting Analog, Short Acting Insulin, Premixed Analog, Premixed Insulin, and Long-acting Analog), Sources (Analogs and Human Recombinant Insulin), Applications (Type I Diabetes and Type II Diabetes), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global CIS insulin market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing prevalence of diabetes across the globe due to changing lifestyle of people.
A peptide hormone produced by the pancreas is one of the key hormones for the human body. It helps the regulation of glucose into the blood cells and regulates the metabolism of fats and carbohydrates. When insulin is not produced in a sufficient amount in the body, it leads to sugar accumulation in the blood that results in diabetes. Diabetes is treated by providing insulin externally to the patient. As per the estimation by the International Diabetes Federation, the number of diabetic patients is expected to grow from 366 million in 2011 to 552 million in 2030. The report also stated that in 2013 approximately 382 million individuals were diagnosed with diabetes. Hence the rapid increase in the number of diabetic patients is expected to drive the market expansion.
There are about 100 million individuals around the world who need insulin. This also includes the number of patients who are suffering from type I and type II diabetes. Insulin has been used for the treatment of diabetes for over 90 years; however, still many people in need across several parts of regions are unable to afford and access it. In order to prevent complications, type I diabetic patients are treated with insulin to maintain the sugar level in their blood along with taking care of their lifestyle and diet.
Market Trends, Drivers, Restraints, and Opportunities
- Wide consumption of the fast-food products and high intake of sugar-based food products are anticipated to fuel the market growth during the forecast period.
- Commercialization of insulin products at a very large scale leads to deeper penetration among patients, which is anticipated to drive the market expansion in the coming years.
- Launch of new products in the market coupled with the establishment of regulations that favors the CIS insulin manufacturers present a major driver to boost the market growth.
- Rising geriatric population base along with the growing development of low price of insulin products is estimated to drive the market growth during the forecast period.
- High cost of insulin and difficulty in its accessibility are key restraining factors anticipated to restrain the market growth.
- Ongoing research & development activities by insulin developers coupled with agreements made between the local governments are projected to present key lucrative opportunities for market growth.
Scope of the Report
The report on the global CIS insulin market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
CIS Insulin Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Products (Intermediate Insulin, Rapid Acting Analog, Short Acting Insulin, Premixed Analog, Premixed Insulin, and Long-acting Analog), Sources (Analogs and Human Recombinant Insulin), and Applications (Type I Diabetes and Type II Diabetes) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon |
Market Segment Insights
Long-acting analog segment is anticipated to dominate the market
On the basis of products, the global CIS insulin market is divided into intermediate insulin, rapid acting analog, short acting insulin, premixed analog, premixed insulin, and long-acting analog. The long-acting analog segment held a large revenue share of the market in 2019 and is anticipated to dominate the market during the forecast period owing to its high cost.
Analogs segment is expected to account for a major revenue share
Based on sources, the market is bifurcated into analogs and human recombinant insulin. Several insulin products are derived from various sources. The analogs segment is expected to account for a major revenue share of the market during the projected period owing to the penetration of various new products deep in the market.
Type I diabetes segment is estimated to exhibit high revenue growth
On the basis of applications, the global CIS insulin market is bifurcated into type I diabetes and type II diabetes. The type I diabetes segment is estimated to exhibit high revenue growth of the market in the coming years owing to the increasing use of insulin for the treatment of type I diabetes along with the introduction of various new products in the market.
Europe is expected to dominate the market
In terms of regions, the global CIS insulin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to dominate the market during the forecast period in terms of revenue attributed to subsidies provided by different governments in the region so that the medicines are easily accessible and affordable to common people. The further acceleration of the regional market growth is attributed to the well-establishment of healthcare service systems provided by the governments and wide funding for the development of biosimilar products.
Segments
The global CIS insulin market has been segmented on the basis of
Products
- Intermediate Insulin
- Rapid Acting Analog
- Short Acting Insulin
- Premixed Analog
- Premixed Insulin
- Long-acting Analog
Sources
- Analogs
- Human Recombinant Insulin
Applications
- Type I Diabetes
- Type II Diabetes
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Boehringer Ingelheim
- Novo Nordisk
- Sanofi Aventis
- Takeda Pharmaceuticals
- Nanjing Xinbai Pharmaceutical Co. Ltd.
- Merck & Co. Inc.
- Oramed Pharmaceuticals
- Eli Lilly and Co.
- Biocon
Competitive Landscape
Key players competing in the global CIS insulin market are Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. CIS Insulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. CIS Insulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. CIS Insulin Market - Supply Chain
4.5. Global CIS Insulin Market Forecast
4.5.1. CIS Insulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. CIS Insulin Market Size (000’ Units) and Y-o-Y Growth
4.5.3. CIS Insulin Market Absolute $ Opportunity
5. Global CIS Insulin Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. CIS Insulin Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global CIS Insulin Demand Share Forecast, 2019-2026
6. North America CIS Insulin Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America CIS Insulin Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America CIS Insulin Demand Share Forecast, 2019-2026
7. Latin America CIS Insulin Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America CIS Insulin Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America CIS Insulin Demand Share Forecast, 2019-2026
8. Europe CIS Insulin Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe CIS Insulin Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe CIS Insulin Demand Share Forecast, 2019-2026
9. Asia Pacific CIS Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific CIS Insulin Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific CIS Insulin Demand Share Forecast, 2019-2026
10. Middle East & Africa CIS Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa CIS Insulin Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa CIS Insulin Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global CIS Insulin Market: Market Share Analysis
11.2. CIS Insulin Distributors and Customers
11.3. CIS Insulin Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Boehringer Ingelheim
11.4.2. Novo Nordisk
11.4.3. Sanofi Aventis
11.4.4. Takeda Pharmaceuticals
11.4.5. Nanjing Xinbai Pharmaceutical Co. Ltd.
11.4.6. Merck & Co. Inc.
11.4.7. Oramed Pharmaceuticals
2. Assumptions and Acronyms Used
3. Research Methodology
4. CIS Insulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. CIS Insulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. CIS Insulin Market - Supply Chain
4.5. Global CIS Insulin Market Forecast
4.5.1. CIS Insulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. CIS Insulin Market Size (000’ Units) and Y-o-Y Growth
4.5.3. CIS Insulin Market Absolute $ Opportunity
5. Global CIS Insulin Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. CIS Insulin Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global CIS Insulin Demand Share Forecast, 2019-2026
6. North America CIS Insulin Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America CIS Insulin Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America CIS Insulin Demand Share Forecast, 2019-2026
7. Latin America CIS Insulin Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America CIS Insulin Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America CIS Insulin Demand Share Forecast, 2019-2026
8. Europe CIS Insulin Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe CIS Insulin Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe CIS Insulin Demand Share Forecast, 2019-2026
9. Asia Pacific CIS Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific CIS Insulin Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific CIS Insulin Demand Share Forecast, 2019-2026
10. Middle East & Africa CIS Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa CIS Insulin Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa CIS Insulin Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global CIS Insulin Market: Market Share Analysis
11.2. CIS Insulin Distributors and Customers
11.3. CIS Insulin Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Boehringer Ingelheim
11.4.2. Novo Nordisk
11.4.3. Sanofi Aventis
11.4.4. Takeda Pharmaceuticals
11.4.5. Nanjing Xinbai Pharmaceutical Co. Ltd.
11.4.6. Merck & Co. Inc.
11.4.7. Oramed Pharmaceuticals
The global CIS insulin market has been segmented on the basis of
Products
- Intermediate Insulin
- Rapid Acting Analog
- Short Acting Insulin
- Premixed Analog
- Premixed Insulin
- Long-acting Analog
Sources
- Analogs
- Human Recombinant Insulin
Applications
- Type I Diabetes
- Type II Diabetes
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Boehringer Ingelheim
- Novo Nordisk
- Sanofi Aventis
- Takeda Pharmaceuticals
- Nanjing Xinbai Pharmaceutical Co. Ltd.
- Merck & Co. Inc.
- Oramed Pharmaceuticals
- Eli Lilly and Co.
- Biocon
Key players competing in the global CIS insulin market are Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
Our Clients
Related Reports
Some other reports from this category!
